139
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

, , , , , , , , , , , , , , , & show all
Pages 1271-1281 | Received 12 Jul 2023, Accepted 25 Oct 2023, Published online: 11 Nov 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.